05Jul 2022
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan‐L‐CN randomized controlled trial

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan‐L‐CN randomized controlled trial

To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes (T2D), advancing therapy from basal insulin ± oral antihyperglycaemic drugs. iGlarLixi provided better glycaemic control and facilitated more participants to reach glycaemic targets alongside beneficial effects on body weight, with no additional risk of hypoglycaemia. Few gastrointestinal AEs, support iGlarLixi use as an efficacious and well-tolerated therapy option in Chinese people with long‐standing T2D advancing therapy from basal insulin.

  • #endo-diabetology

Like

Save

Share